WO2024008904A3 - Composés isvd hautement puissants capables de remplacer fviii(a) - Google Patents

Composés isvd hautement puissants capables de remplacer fviii(a) Download PDF

Info

Publication number
WO2024008904A3
WO2024008904A3 PCT/EP2023/068805 EP2023068805W WO2024008904A3 WO 2024008904 A3 WO2024008904 A3 WO 2024008904A3 EP 2023068805 W EP2023068805 W EP 2023068805W WO 2024008904 A3 WO2024008904 A3 WO 2024008904A3
Authority
WO
WIPO (PCT)
Prior art keywords
isvd
highly potent
fviii
substituting
haemophilia
Prior art date
Application number
PCT/EP2023/068805
Other languages
English (en)
Other versions
WO2024008904A2 (fr
Inventor
Andreas VEGGE
Daniele GRANATA
Eva Johansson
Jais Rose Bjelke
Jacob LUND
Philip Jonas Sassene
Per J. GREISEN
Thomas Egebjerg
Frantisek Hubalek
Simone FULLE
Mathias Norrman
Marie-Ange Buyse
Evelyn De Tavernier
Soren Steffensen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of WO2024008904A2 publication Critical patent/WO2024008904A2/fr
Publication of WO2024008904A3 publication Critical patent/WO2024008904A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des dérivés de polypeptides ISVD capables de se lier au facteur IX(a) et au facteur X(a) de coagulation qui sont très puissants et fournissent une demi-vie suffisamment longue pour permettre une administration sous-cutanée et perorale efficace. Les dérivés de polypeptides ISVD de l'invention sont ainsi appropriés pour le traitement de l'hémophilie A, de l'hémophilie A avec des inhibiteurs et de l'hémophilie A acquise par diverses voies d'administration comprenant une administration sous-cutanée et perorale.
PCT/EP2023/068805 2022-07-08 2023-07-07 Composés isvd hautement puissants capables de remplacer fviii(a) WO2024008904A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22183825 2022-07-08
EP22183825.3 2022-07-08

Publications (2)

Publication Number Publication Date
WO2024008904A2 WO2024008904A2 (fr) 2024-01-11
WO2024008904A3 true WO2024008904A3 (fr) 2024-02-22

Family

ID=82403465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/068805 WO2024008904A2 (fr) 2022-07-08 2023-07-07 Composés isvd hautement puissants capables de remplacer fviii(a)

Country Status (1)

Country Link
WO (1) WO2024008904A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7459354B2 (ja) * 2022-07-08 2024-04-01 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180140673A1 (en) * 2014-12-23 2018-05-24 Novo Nordisk A/S FGF21 Derivatives and Uses Thereof
WO2019096874A1 (fr) * 2017-11-15 2019-05-23 Novo Nordisk A/S Liants de facteur x renforçant l'activation fx
CN110343181A (zh) * 2018-04-08 2019-10-18 苏州康宁杰瑞生物科技有限公司 针对凝血因子ix(fix)的单域抗体
WO2019215063A1 (fr) * 2018-05-07 2019-11-14 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique
US20210284715A1 (en) * 2017-02-06 2021-09-16 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
CN113880951A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192131A1 (fr) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
CA2390691C (fr) 1999-12-24 2016-05-10 Genentech, Inc. Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
WO2007121318A2 (fr) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Préparations destinées à l'administration d'insuline
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
CA3051639A1 (fr) 2017-02-01 2018-08-09 Novo Nordisk A/S Anticorps procoagulants
UA128389C2 (uk) 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
PE20211399A1 (es) 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
CN115052898A (zh) 2020-01-30 2022-09-13 诺和诺德股份有限公司 双特异性因子viii模拟抗体

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180140673A1 (en) * 2014-12-23 2018-05-24 Novo Nordisk A/S FGF21 Derivatives and Uses Thereof
US20210284715A1 (en) * 2017-02-06 2021-09-16 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
WO2019096874A1 (fr) * 2017-11-15 2019-05-23 Novo Nordisk A/S Liants de facteur x renforçant l'activation fx
US20210054097A1 (en) * 2017-11-15 2021-02-25 Novo Nordisk A/S Factor x binders enhancing fx activation
CN110343181A (zh) * 2018-04-08 2019-10-18 苏州康宁杰瑞生物科技有限公司 针对凝血因子ix(fix)的单域抗体
WO2019215063A1 (fr) * 2018-05-07 2019-11-14 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique
CN113880951A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Challenges in Delivery of Therapeutic Genomics and Proteomics", 1 January 2011, ELSEVIER, ISBN: 978-0-12-384964-9, article PATEL GAURANG ET AL: "Oral Delivery of Proteins and Peptides", pages: 481 - 529, XP093083924, DOI: 10.1016/B978-0-12-384964-9.00010-4 *
ABRAMSON ALEX ET AL: "Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 40, no. 1, 30 August 2021 (2021-08-30), pages 103 - 109, XP037667058, ISSN: 1087-0156, [retrieved on 20210830], DOI: 10.1038/S41587-021-01024-0 *
KNIGHT TRISTAN ET AL: "Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation", vol. 11, no. 22, 24 October 2016 (2016-10-24), DE, pages 2474 - 2495, XP055820503, ISSN: 1860-7179, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcmdc.201600374> DOI: 10.1002/cmdc.201600374 *
KNIGHT TRISTAN ET AL: "The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A", vol. 9, no. 10, 1 October 2018 (2018-10-01), GB, pages 319 - 334, XP093024109, ISSN: 2040-6207, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187429/pdf/10.1177_2040620718799997.pdf> DOI: 10.1177/2040620718799997 *
T. IGAWA ET AL: "Reduced elimination of IgG antibodies by engineering the variable region", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 23, no. 5, 1 May 2010 (2010-05-01), pages 385 - 392, XP055003115, ISSN: 1741-0126, DOI: 10.1093/protein/gzq009 *
ZHU QUANGANG ET AL: "Oral delivery of proteins and peptides: Challenges, status quo and future perspectives", ACTA PHARMACEUTICA SINICA B, vol. 11, no. 8, 1 August 2021 (2021-08-01), pages 2416 - 2448, XP093086870, ISSN: 2211-3835, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/280688/1-s2.0-S2211383521X00081/1-s2.0-S2211383521001167/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEKv//////////wEaCXVzLWVhc3QtMSJHMEUCIFAquQo80tXJ9LrU7bdzRi/vrIB9U7mMT2cAc4yQ24C9AiEAy02IgF8GdA+7AqPEW7KH6ROIRZrYMCUOE9KJTSQwOsoqvAUIpP//////////ARAFGgwwNTkwMDM1N> DOI: 10.1016/j.apsb.2021.04.001 *

Also Published As

Publication number Publication date
WO2024008904A2 (fr) 2024-01-11

Similar Documents

Publication Publication Date Title
ATE549028T1 (de) Stabile analoga von glp-1
WO2024008904A3 (fr) Composés isvd hautement puissants capables de remplacer fviii(a)
ES2149761T3 (es) Derivado de piridazinona.
EA200701596A1 (ru) ПРЕПАРАТ АНТИТЕЛА ПРОТИВ Аβ-ПЕПТИДА
DK0951474T3 (da) Nye cyclosporinderivater, deres fremstilling og farmaceutiske præparater deraf
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
ATE98245T1 (de) Azaindene.
DE3482589D1 (de) Retro-inverse analoga des bradykinin-potentialisierenden peptids bpp-5a und verfahren zu ihrer herstellung.
NO20072997L (no) Posisjonsstyrt omdanning av FVIII
DK0948527T3 (da) Cylosporinderivater, fremstilling af disse og farmaceutiske præparater indeholdende disse
EA200000872A1 (ru) Способы лечения диабета с помощью пептидных аналогов инсулина
CY1114241T1 (el) Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια
ATE254630T1 (de) Cyclosporine
DE60133323D1 (de) Cardioprotektive Phosphonate
BR112023006761A2 (pt) Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
NO20032261D0 (no) Medisinske preparater
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
BR0312889A (pt) Polipeptìdeo t20 peguilado
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
BR0315620A (pt) Derivados de n-benzodioxolil, n-benzodioxanil e n-benzodioxepinil arilcarboxamida, e composições farmacêuticas compreendendo os mesmos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23741620

Country of ref document: EP

Kind code of ref document: A2